{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:46Z","timestamp":1786984366545,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","americanjournalofsurgery.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.amjsurg.2024.116129","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:39:14Z","timestamp":1733229554000},"page":"116129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Changes in the surgical management of melanoma and measures to implement change"],"prefix":"10.1016","volume":"241","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5408-3750","authenticated-orcid":false,"given":"Laurence E.","family":"McCahill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjsurg.2024.116129_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1245\/s10434-019-07866-y","article-title":"The landmark series: randomized trials examining surgical margins for cutaneous melanoma","volume":"27","author":"Angeles","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.amjsurg.2024.116129_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","article-title":"Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial","volume":"242","author":"Morton","year":"2005","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.amjsurg.2024.116129_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjsurg.2024.116129_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics: Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.amjsurg.2024.116129_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae insights: melanoma: cutaneous, version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"1","key":"10.1016\/j.amjsurg.2024.116129_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1245\/s10434-019-07830-w","article-title":"The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes)","volume":"27","author":"Bello","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.amjsurg.2024.116129_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.amjsurg.2024.116129_bib8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.amjsurg.2024.116129_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1245\/s10434-018-7006-4","article-title":"Microsatellitosis in patients with melanoma","volume":"26","author":"Karakousis","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.amjsurg.2024.116129_bib10","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1245\/s10434-018-6812-z","article-title":"The role of completion lymph node dissection for sentinel lymph node-positive melanoma","volume":"26","author":"Hieken","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.amjsurg.2024.116129_bib11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.amjsurg.2024.116129_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.amjsurg.2024.116129_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.amjsurg.2024.116129_bib14","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.amjsurg.2024.116129_bib15","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1245\/s10434-018-6470-1","article-title":"1 versus 2-cm excision margins for pT2-pT4 primary cutaneous melanoma (MelMarT): a feasibility study","volume":"25","author":"Moncrieff","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2024.116129_bib16","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-022-11766-z","article-title":"A\u00a0phase III, multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II)","author":"Rossi","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.amjsurg.2024.116129_bib17","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"34","key":"10.1016\/j.amjsurg.2024.116129_bib18","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.21.02488","article-title":"Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: implications for the management of American joint committee on cancer IIIA disease","volume":"40","author":"Moncrieff","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.amjsurg.2024.116129_bib19","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.amjsurg.2024.116129_bib20","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.amjsurg.2024.116129_bib21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/jamasurg.2023.7451","article-title":"Optimal practices for suspected nodal melanoma-the role of the general surgeon","volume":"159","author":"Rog","year":"2024","journal-title":"JAMA Surg"},{"issue":"7","key":"10.1016\/j.amjsurg.2024.116129_bib22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.amjsurg.2024.116129_bib23","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.amjsurg.2024.116129_bib24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/bjs.11168","article-title":"Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma","volume":"106","author":"Schermers","year":"2019","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.amjsurg.2024.116129_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","article-title":"Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma","volume":"157","author":"Reijers","year":"2022","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.amjsurg.2024.116129_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.amjsurg.2024.116129_bib27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.amjsurg.2024.116129_bib28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961024006810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961024006810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:35:10Z","timestamp":1739190910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961024006810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"alternative-id":["S0002961024006810"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2024.116129","relation":{},"ISSN":["0002-9610"],"issn-type":[{"value":"0002-9610","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in the surgical management of melanoma and measures to implement change","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2024.116129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116129"}}